Vasodilators may emerge as Potential Treatment Option for Rosacea: Study

Initially, in this study, they hypothesized that antihypertensives worsen the rosacea. However, what they found was quite opposite. Dr Jennifer G. Powers, MD, in an interview, said, "What we found was exactly the opposite — that in fact their presence in a medical chart correlated with lower rates of rosacea diagnoses, as defined by ICD 9/10 codes."

The researchers identified a total of 680 hypertensive patients being treated with vasodilators or a thiazide diuretic in whom rosacea developed within 5 years of initiating therapy between June 1, 2006, and April 31, 2019. Researchers randomly assigned the patients to receive either thiazide (control arm, n=127) or Vasodilators (intervention arm, n=553).

Key findings of the study were:

• Upon analysis, the researchers found that the use of vasodilators had a protective effect on the development of rosacea within five years, compared with thiazides (relative risk [RR], 0.56).
• They noted that the , the relative risk was 0.50 for ACE-inhibitors (P less than .0001); 0.69 for ARBs (P = .041); 0.55 for beta-blockers (P less than .0001); and 0.39 for CCBs (P less than .0001).
• They observed significant inverse correlations in ACE-inhibitors, beta-blockers, and CCBs among White women aged 50 and older, but not with non-White subgroups.

The authors concluded, "chronic use (of vasodilators) in patients with hypertension may reduce damage to peripheral vessels, and thus decrease risk of rosacea."

For further information:

https://www.jaad.org/article/S0190-9622(20)33243-6/fulltext